Tag: Dr Ashley Dombkowski

alladapt

FDA Fast Tracks Alladapt’s ADP101 for the Treatment of Single and...

Fast Track Designation accelerates ADP101's development path for the treatment of food allergies.
Alladapt Harmony Study

Alladapt Announces Positive Results for Multi-Allergen OIT Candidate from Phase 1/2...

OIT candidate treats allergies to the Top 9 allergens at the same time.
Alladapt Harmony Study

Alladapt’s 15-Allergen OIT Candidate Ready to Begin Phase 1/2 Study

ADP101 is intended to treat patients with an allergy to one or more of peanut, almond, hazelnut, cashew, pistachio, pecan, walnut, milk, egg, cod, salmon, shrimp, wheat, soy, and sesame.
Harmony Study

Alladapt Enrolling Participants for Clinical Study of OIT Therapy to Treat...

The study is still seeking participants 4-55 years of age.
Alladapt

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development...

Company is developing therapy to target a number of food allergies simultaneously.